JIA
MCID: JVN010
MIFTS: 67

Juvenile Rheumatoid Arthritis (JIA)

Categories: Bone diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Juvenile Rheumatoid Arthritis

MalaCards integrated aliases for Juvenile Rheumatoid Arthritis:

Name: Juvenile Rheumatoid Arthritis 12 75 53 25 59 6 15 72 33
Juvenile Idiopathic Arthritis 12 53 25 59 37 15 17
Juvenile Arthritis 53 43 72 33
Juvenile Chronic Arthritis 53 25 59
Monarticular Juvenile Rheumatoid Arthritis 12 72
Systemic Juvenile Rheumatoid Arthritis 12 25
Pauciarticular Juvenile Arthritis 12 33
Juvenile Chronic Polyarthritis 12 72
Arthritis, Juvenile Rheumatoid 53 25
Acute Polyarticular Juvenile Rheumatoid Arthritis 72
Pauciarticular Onset Juvenile Chronic Arthritis 12
Pauciarticular Juvenile Rheumatoid Arthritis 72
Rheumatoid Arthritis, Systemic Juvenile 72
Acute Juvenile Rheumatoid Arthritis 12
Arthritis Juvenile Rheumatoid 55
Juvenile Ra 25
Jia 25
Jra 25

Characteristics:

Orphanet epidemiological data:

59
juvenile idiopathic arthritis
Prevalence: 1-9/100000 (Europe),1-9/100000 (France); Age of onset: Childhood;

Classifications:



External Ids:

Disease Ontology 12 DOID:676
KEGG 37 H01672
MESH via Orphanet 45 D001171
ICD10 via Orphanet 34 M08.0 M08.1 M08.2 more
UMLS via Orphanet 73 C0553662 C1444838 C3495559
Orphanet 59 ORPHA92
UMLS 72 C0157916 C0157917 C0157918 more

Summaries for Juvenile Rheumatoid Arthritis

Genetics Home Reference : 25 Juvenile idiopathic arthritis refers to a group of conditions involving joint inflammation (arthritis) that first appears before the age of 16. This condition is an autoimmune disorder, which means that the immune system malfunctions and attacks the body's organs and tissues, in this case the joints. Researchers have described seven types of juvenile idiopathic arthritis. The types are distinguished by their signs and symptoms, the number of joints affected, the results of laboratory tests, and the family history. Systemic juvenile idiopathic arthritis causes inflammation in one or more joints. A high daily fever that lasts at least 2 weeks either precedes or accompanies the arthritis. Individuals with systemic arthritis may also have a skin rash or enlargement of the lymph nodes (lymphadenopathy), liver (hepatomegaly), or spleen (splenomegaly). Oligoarticular juvenile idiopathic arthritis (also known as oligoarthritis) is marked by the occurrence of arthritis in four or fewer joints in the first 6 months of the disease. It is divided into two subtypes depending on the course of disease. If the arthritis is confined to four or fewer joints after 6 months, then the condition is classified as persistent oligoarthritis. If more than four joints are affected after 6 months, this condition is classified as extended oligoarthritis. Individuals with oligoarthritis are at increased risk of developing inflammation of the eye (uveitis). Rheumatoid factor positive polyarticular juvenile idiopathic arthritis (also known as polyarthritis, rheumatoid factor positive) causes inflammation in five or more joints within the first 6 months of the disease. Individuals with this condition also have a positive blood test for proteins called rheumatoid factors. This type of arthritis closely resembles rheumatoid arthritis as seen in adults. Rheumatoid factor negative polyarticular juvenile idiopathic arthritis (also known as polyarthritis, rheumatoid factor negative) is also characterized by arthritis in five or more joints within the first 6 months of the disease. Individuals with this type, however, test negative for rheumatoid factor in the blood. Psoriatic juvenile idiopathic arthritis involves arthritis that usually occurs in combination with a skin disorder called psoriasis. Psoriasis is a condition characterized by patches of red, irritated skin that are often covered by flaky white scales. Some affected individuals develop psoriasis before arthritis while others first develop arthritis. Other features of psoriatic arthritis include abnormalities of the fingers and nails or eye problems. Enthesitis-related juvenile idiopathic arthritis is characterized by tenderness where the bone meets a tendon, ligament, or other connective tissue. The most commonly affected places are the hips, knees, and feet. This tenderness, known as enthesitis, accompanies the joint inflammation of arthritis. Enthesitis-related arthritis may also involve inflammation in parts of the body other than the joints. The last type of juvenile idiopathic arthritis is called undifferentiated arthritis. This classification is given to affected individuals who do not fit into any of the above types or who fulfill the criteria for more than one type of juvenile idiopathic arthritis.

MalaCards based summary : Juvenile Rheumatoid Arthritis, also known as juvenile idiopathic arthritis, is related to rheumatoid factor-negative juvenile idiopathic arthritis and rheumatoid arthritis, systemic juvenile, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Juvenile Rheumatoid Arthritis is IL6 (Interleukin 6), and among its related pathways/superpathways are Cytokine-cytokine receptor interaction and JAK-STAT signaling pathway. The drugs Naproxen and Esomeprazole have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and t cells, and related phenotypes are arthritis and fever

Disease Ontology : 12 A rheumatoid arthritis that involves an autoimmune disease onset in children under 16 which attacks the healthy cells and tissue of located in joint.

NIH Rare Diseases : 53 Juvenile idiopathic arthritis is an autoimmune condition that causes pain and swelling in a child's joints. When the immune system attacks the tissues of the joints, the resulting inflammation can cause joint damage, resulting in the pain and swelling characteristic of the disease. Some children who have juvenile idiopathic arthritis are affected by episodes where the symptoms worsen, called flares. Like most other autoimmune conditions, juvenile idiopathic arthritis is caused by a combination of genetic and environmental factors. To be diagnosed with juvenile idiopathic arthritis, the symptoms must have begun before age 16. Diagnosis of the condition may be based on blood tests, X-rays, and ruling out other similar conditions. Treatment options may include medications and physical therapy.

MedlinePlus : 43 Juvenile arthritis (JA) is arthritis that happens in children. It causes joint swelling, pain, stiffness, and loss of motion. It can affect any joint, but is more common in the knees, hands, and feet. In some cases it can affect internal organs as well. The most common type of JA that children get is juvenile idiopathic arthritis. There are several other forms of arthritis affecting children. One early sign of JA may be limping in the morning. Symptoms can come and go. Some children have just one or two flare-ups. Others have symptoms that never go away. JA can cause growth problems and eye inflammation in some children. No one knows exactly what causes JA. Most types are autoimmune disorders. This means that your immune system, which normally helps your body fight infection, attacks your body's own tissues. JA can be hard to diagnose. Your health care provider may do a physical exam, lab tests, and x-rays. A team of providers usually treats JA. Medicines and physical therapy can help maintain movement and reduce swelling and pain. They may also help prevent and treat complications. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

KEGG : 37
Juvenile idiopathic arthritis (JIA) is one of the most common childhood rheumatic diseases. Clinically, it is defined as arthritis of unknown origin that starts before the age of 16, and persists for at least 6 weeks. Next to a certain genetic predisposition, environmental factors play a role leading to a chronic inflammatory response. JIA is not a single disorder but consists of a heterogeneous group of auto-immune inflammatory diseases. It has variable rates in course and activity of disease. Based on 6 months of clinical symptoms and global prognostic factors, the following clinical subtypes of JIA are recognized: systemic JIA, oligoarthritis, RF-negative polyarthritis, RF-positive polyarthritis, psoriatic JIA, enthesitis- related arthritis, and undifferentiated arthritis. Systemic JIA, also known as Still's disease, is a subtype with strong systemic clinical symptoms. Patients with systemic JIA have, in addition to arthritis, prominent symptoms of systemic inflammation such as spiking fever, rash, pericarditis, peritonitis, lymphadenopathy and organomegaly. A severe and often life-threatening complication occurring in 10-30% of patients with systemic JIA is macrophage activation syndrome. Polymorphisms in the IL6 and in the MIF gene have been found to be associated with susceptibility to the disorder. Based on the known relevance of IL6 in JIA pathophysiology, tocilizumab has been investigated and approved for use in the treatment of systemic and polyarticular JIA.

Wikipedia : 75 Juvenile idiopathic arthritis (JIA), is the most common form of arthritis in children and adolescents.... more...

Related Diseases for Juvenile Rheumatoid Arthritis

Diseases in the Rheumatoid Arthritis family:

Rheumatoid Arthritis, Systemic Juvenile Juvenile Rheumatoid Arthritis

Diseases related to Juvenile Rheumatoid Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 905)
# Related Disease Score Top Affiliating Genes
1 rheumatoid factor-negative juvenile idiopathic arthritis 34.3 SLC11A1 IL2RA HLA-DRB1
2 rheumatoid arthritis, systemic juvenile 34.2 IL6 IL1R1 HLA-DRB1
3 oligoarticular juvenile idiopathic arthritis 33.8 TNF IL2RA HLA-DRB1 HLA-DQA1 HLA-DPB1
4 systemic onset juvenile idiopathic arthritis 33.2 TNF IL18
5 uveitis 32.0 TNF IL2RA IL1R1
6 spondyloarthropathy 1 31.5 TNFRSF1B TNF CRP
7 rubella 31.3 TNF HLA-DRB1 HLA-DPB1
8 vasculitis 31.1 TNFRSF1B TNF S100A9 CRP
9 optic neuritis 31.0 TNF LTA HLA-DRB1
10 bronchiolitis 31.0 TNF IL6 CRP
11 exanthem 31.0 TNFRSF1B TNF IL6 IL1RN CRP
12 rheumatic fever 31.0 TNF IL6 HLA-DRB1 HLA-DQA1
13 endocarditis 31.0 TNF IL6 CRP
14 posterior uveitis 30.9 TNF IL6 IL2RA
15 end stage renal failure 30.8 TNF IL6 CRP
16 purpura 30.8 TNF IL6 CRP
17 intermediate uveitis 30.8 TNF IL6 IL2RA
18 cholangitis 30.8 TNF IL6 HLA-DRB1 CRP
19 atherosclerosis susceptibility 30.8 TNF IL6 CRP
20 mixed connective tissue disease 30.7 TNF IL6 HLA-DRB1
21 juvenile ankylosing spondylitis 30.7 TNFRSF1B TNF IL6 IL1RN
22 connective tissue disease 30.7 TNF IL6 HLA-DRB1 HLA-DQA1 HLA-DPB1
23 pustulosis of palm and sole 30.7 TNFRSF1B TNF IL1RN
24 panuveitis 30.6 TNFRSF1B TNF HLA-DRB1
25 skin sarcoidosis 30.6 TNFRSF1B TNF
26 fasciitis 30.6 TNF IL6 IL18
27 spondylitis 30.6 TNFRSF1B TNF LTA IL6 IL1RN CRP
28 granulomatous dermatitis 30.5 TNFRSF1B TNF
29 keratoconjunctivitis sicca 30.4 TNF IL6 IL1B
30 sleep disorder 30.4 IL6 HAPLN1 CRP
31 cryopyrin-associated periodic syndrome 30.4 IL6 IL1RN IL1R1 CRP
32 autoimmune disease 30.3 TNF IL6 IL2RA IL1B HLA-DRB1
33 kawasaki disease 30.3 TNF S100A12 IL6 CRP
34 chlamydia pneumonia 30.3 HLA-DPB1 CRP
35 alopecia areata 30.3 TNF IL2RA IL1RN
36 guillain-barre syndrome 30.3 TNFRSF1B TNF HLA-DQA1
37 mumps 30.2 TNF IL2RA HLA-DRB1 HLA-DPB1
38 lyme disease 30.2 TNF IL6 IL1B CRP
39 adult-onset still's disease 30.2 TNF IL6 IL1RN IL1R1 IL1B IL18
40 acute graft versus host disease 30.2 TNF IL2RA IL18
41 pharyngitis 30.2 IL1B HLA-DRB1 CRP
42 gastroenteritis 30.1 TNF IL6 IL1B CRP
43 neonatal lupus erythematosus 30.1 HLA-DQA1 HLA-DPB1
44 pericarditis 30.0 TNF IL6 IL1RN IL1B CRP
45 temporal arteritis 30.0 TNF IL6 IL1RN HLA-DRB1 CRP
46 sleep apnea 30.0 TNF IL6 IL1B CRP
47 periodontitis 30.0 TNF IL6 IL1B CRP BGLAP
48 peritonitis 30.0 TNF IL6 IL1B CRP
49 osteomyelitis 29.9 TNF IL6 IL1RN IL1B
50 pneumonia 29.9 TNF IL6 IL1B CRP

Graphical network of the top 20 diseases related to Juvenile Rheumatoid Arthritis:



Diseases related to Juvenile Rheumatoid Arthritis

Symptoms & Phenotypes for Juvenile Rheumatoid Arthritis

Human phenotypes related to Juvenile Rheumatoid Arthritis:

59 32 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthritis 59 32 hallmark (90%) Very frequent (99-80%) HP:0001369
2 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
3 arthralgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002829
4 autoimmunity 59 32 hallmark (90%) Very frequent (99-80%) HP:0002960
5 joint dislocation 59 32 frequent (33%) Frequent (79-30%) HP:0001373
6 joint stiffness 59 32 frequent (33%) Frequent (79-30%) HP:0001387
7 malabsorption 59 32 frequent (33%) Frequent (79-30%) HP:0002024
8 joint swelling 59 32 frequent (33%) Frequent (79-30%) HP:0001386
9 generalized hyperkeratosis 59 32 frequent (33%) Frequent (79-30%) HP:0005595
10 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
11 skin rash 59 32 frequent (33%) Frequent (79-30%) HP:0000988
12 psoriasiform dermatitis 59 32 frequent (33%) Frequent (79-30%) HP:0003765
13 abnormality of the pleura 59 32 frequent (33%) Frequent (79-30%) HP:0002103
14 uveitis 59 32 frequent (33%) Frequent (79-30%) HP:0000554
15 mediastinal lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0100721
16 nail pits 59 32 frequent (33%) Frequent (79-30%) HP:0001803
17 cartilage destruction 59 32 frequent (33%) Frequent (79-30%) HP:0100773
18 abnormality of the sacroiliac joint 59 32 frequent (33%) Frequent (79-30%) HP:0100781
19 abnormal fingernail morphology 32 frequent (33%) HP:0001231
20 splenomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0001744
21 hepatomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0002240
22 pericardial effusion 59 32 occasional (7.5%) Occasional (29-5%) HP:0001698
23 abnormality of the nail 59 Frequent (79-30%)
24 thickened skin 59 Frequent (79-30%)
25 abnormality of the fingernails 59 Frequent (79-30%)
26 abnormal joint morphology 59 Frequent (79-30%)

UMLS symptoms related to Juvenile Rheumatoid Arthritis:


back pain, sciatica, muscle cramp

GenomeRNAi Phenotypes related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance GR00327-A 9.02 BGLAP HAPLN1 HLA-DPB1 IL1RN SLC11A1

MGI Mouse Phenotypes related to Juvenile Rheumatoid Arthritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 HAPLN1 HLA-DQA1 IL18 IL1B IL1R1 IL1RN
2 homeostasis/metabolism MP:0005376 10.03 CRP DEK IL18 IL1B IL1R1 IL1RN
3 cardiovascular system MP:0005385 10.02 CRP IL18 IL1B IL1R1 IL1RN IL6
4 immune system MP:0005387 9.97 CRP HLA-DQA1 IL18 IL1B IL1R1 IL1RN
5 mortality/aging MP:0010768 9.73 HAPLN1 IL18 IL1B IL1R1 IL1RN IL2RA
6 neoplasm MP:0002006 9.17 DEK IL1B IL1R1 IL6 SLC11A1 TNF

Drugs & Therapeutics for Juvenile Rheumatoid Arthritis

Drugs for Juvenile Rheumatoid Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
2
Esomeprazole Approved, Investigational Phase 4 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
3
Histamine Approved, Investigational Phase 4 51-45-6 774
4
Famotidine Approved Phase 4 76824-35-6 3325
5
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
6
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
7
Sulfasalazine Approved Phase 4 599-79-1 5359476 5353980
8 Vaccines Phase 4
9 Antacids Phase 4
10 Proton Pump Inhibitors Phase 4
11 Anti-Ulcer Agents Phase 4
12 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
13
Histamine Phosphate Phase 4 51-74-1 65513
14 Histamine Antagonists Phase 4
15 Histamine H2 Antagonists Phase 4
16 Pharmaceutical Solutions Phase 4
17 Central Nervous System Depressants Phase 4
18 Anesthetics Phase 4
19 Adrenergic alpha-2 Receptor Agonists Phase 4
20 Adrenergic Agonists Phase 4
21 Adrenergic alpha-Agonists Phase 4
22 Adrenergic Agents Phase 4
23 Hypnotics and Sedatives Phase 4
24 Anesthetics, General Phase 4
25 Anesthetics, Inhalation Phase 4
26 Liver Extracts Phase 4
27 Analgesics, Non-Narcotic Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29 Gastrointestinal Agents Phase 4
30 Anti-Infective Agents Phase 4
31
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
32
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
33
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 5281106 54677470
34
Infliximab Approved Phase 3 170277-31-3
35
Calcium carbonate Approved, Investigational Phase 3 471-34-1
36
Alendronate Approved Phase 2, Phase 3 66376-36-1, 121268-17-5 2088
37
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
38
Hydroxychloroquine Approved Phase 3 118-42-3 3652
39
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
40
Prilocaine Approved Phase 3 721-50-6 4906
41
Fluoxetine Approved, Vet_approved Phase 3 54910-89-3 3386
42
Tofacitinib Approved, Investigational Phase 3 477600-75-2
43
Certolizumab pegol Approved Phase 3 428863-50-7
44
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
45
leucovorin Approved Phase 3 58-05-9 143 6006
46
Sodium citrate Approved, Investigational Phase 3 68-04-2
47
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
48
Ibuprofen Approved Phase 3 15687-27-1 3672
49
tannic acid Approved Phase 2, Phase 3 1401-55-4
50
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337

Interventional clinical trials:

(show top 50) (show all 238)
# Name Status NCT ID Phase Drugs
1 Study of Therapeutic Effects and Side Effects of Leflunomide in Methotrexate Refractory Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
2 When and in Whom to Stop Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4 etanercept;etanercept
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis. Completed NCT00807846 Phase 4 Celecoxib;Naproxen
5 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
6 Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA) Completed NCT00443430 Phase 4 methotrexate;methotrexate - etanercept - prednisolone arm
7 Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA Completed NCT00792233 Phase 4
8 Short and Long-term Immunogenicity and Safety Following the 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy Completed NCT02196480 Phase 4
9 A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA) Completed NCT01544114 Phase 4 VIMOVO 250/20;VIMOVO 375/20;VIMOVO 500/20
10 A Multicenter, Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis Completed NCT01563185 Phase 4 800 mg ibuprofen/26.6 mg famotidine
11 Tocilizumab, An IL-6 Receptor Antibody, As Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT02034474 Phase 4 Tocilizumab;Placebo
12 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
13 A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis Recruiting NCT03301883 Phase 4 Tocilizumab;NSAIDs;CSs;MTX
14 Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population Recruiting NCT03069638 Phase 4 Dexmedetomidine;Sedatives/Hypnotics,Other
15 A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab Active, not recruiting NCT01734382 Phase 4 Tocilizumab
16 Pilot Study of the Safety and Efficacy of Quadrivalent Human Papillomavirus Vaccine (Gardasil®) in Female Subjects With Juvenile Idiopathic Arthritis (JIA)/ Seronegative Arthritis Active, not recruiting NCT00573651 Phase 4
17 An Open Label Non-randomized Study To Characterize The Steady State Pharmacokinetics Of Sulfasalazine Delayed Release Tablets In Children With Juvenile Idiopathic Arthritis Terminated NCT00637780 Phase 4 Sulfasalazine
18 Double Blind Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid-Associated Osteopenia and Osteoporosis Unknown status NCT00209469 Phase 2, Phase 3 alendronate sodium
19 The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis Unknown status NCT00012506 Phase 3 TNFR:Fc
20 Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
21 An Open-label, Single-arm, Active-treatment, Efficacy and Safety Study of Canakinumab (ACZ885) Administered for at Least 48 Weeks in Japanese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) Completed NCT02396212 Phase 3
22 A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) Completed NCT02334748 Phase 3 canakinumab
23 β-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) Completed NCT02296424 Phase 3 ACZ885 150 mg (Canakinumab)
24 A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis Completed NCT00034853 Phase 3 meloxicam oral suspension;naproxen oral suspension
25 A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis. Completed NCT00279747 Phase 3 meloxicam 0.25 mg/kg;meloxicam 0.125 mg/kg;naproxen 10 mg/kg
26 A Randomized, Double-blind, Placebo Controlled, Withdrawal Study of Flare Prevention of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Completed NCT00889863 Phase 3 canakinumab;placebo
27 Randomized, Double-Blind, Multicenter, Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA Completed NCT00652925 Phase 3 Celecoxib;Celecoxib;Naproxen
28 A Phase III, Multi-Center, Multi-National, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents With Active Polyarticular Juvenile Rheumatoid Arthritis (JRA) Completed NCT00095173 Phase 3 Abatacept;Placebo;Abatacept
29 ANAkinra in Severe Juvenile Idiopathic Arthritis of Systemic Onset (ANAJIS) Completed NCT00339157 Phase 2, Phase 3 Anakinra
30 Childhood Onset Psychiatric Disorders: A Placebo Controlled Double-Blind Crossover Trial of Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3 Intravenous immunoglobulin
31 Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg With Active Juvenile Idiopathic Arthritis (JIA) Completed NCT00775437 Phase 3 Adalimumab
32 A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis Who Have a History of an Inadequate Response or Intolerance to Methotrexate or Biologics Completed NCT01835470 Phase 3 Abatacept
33 Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis From France Who Completed the Global, Multinational Trial (WA19977) Completed NCT01673919 Phase 3 tocilizumab [RoActemra/Actemra]
34 A Multicenter, Open-label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis Completed NCT00690573 Phase 3
35 Effect of Supplementation With 2000 International Units (IU) Vitamin D, 1gm Calcium or Both on Calcium Absorption and Bone Mineralization in Children With Juvenile Rheumatoid Arthritis Completed NCT00570934 Phase 3 Placebo
36 EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS Completed NCT02592434 Phase 3 CP-690,550 (tofacitinib)
37 Recombinant Human Growth Hormone Treatment in Juvenile Idiopathic Arthritis: Controlled Study on the Effect on Growth and Bone Development Completed NCT00420251 Phase 3 Genotropin
38 An Open-label Extension Study of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Who Participated in Studies ACZ885G2301 and ACZ885G2305; and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever Completed NCT00891046 Phase 3 Canakinumab
39 Extension, Open-label, Interventional, Long-term Study to Evaluate the Safety of Tocilizumab Treatment in Patients From Brazil With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global Multinational Trial (WA19977) Completed NCT01727986 Phase 3 tocilizumab [RoActemra/Actemra]
40 Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global, Multinational Trial (WA19977) Completed NCT01667471 Phase 3 tocilizumab [RoActemra/Actemra]
41 An Open-Label, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With pJIA Completed NCT00144664 Phase 3 MRA(Tocilizumab)
42 A Double-Blind, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With sJIA Completed NCT00144599 Phase 3 MRA(Tocilizumab);placebo
43 Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial Completed NCT01385826 Phase 2, Phase 3 Anti-tumor necrosis factor alpha monoclonal antibody;placebo
44 Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis Completed NCT00277251 Phase 2, Phase 3 Alendronate
45 An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety, Efficacy and PK of MRA in Patients With pJIA Who Participated in Study MRA318JP Completed NCT00144625 Phase 3 MRA(Tocilizumab)
46 An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP Completed NCT00144612 Phase 3 MRA(Tocilizumab)
47 A Randomized, Double-Blind Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate for the Treatment of Patients With Polyarticular Juvenile Rheumatoid Arthritis Completed NCT00036374 Phase 3 Infliximab
48 A 24 Week Randomized, Double-blind, Placebo-controlled Withdrawal Trial With a 16 Week Open-label lead-in Phase, and 64 Week Open-label Follow-up, to Evaluate the Effect on Clinical Response and the Safety of Tocilizumab in Patients With Active Polyarticular-course Juvenile Idiopathic Arthritis Completed NCT00988221 Phase 3 Tocilizumab;Placebo
49 A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab Completed NCT00642460 Phase 3 tocilizumab [RoActemra/Actemra];Placebo;Non-steroidal anti-inflammatory drugs (NSAIDs);methotrexate;corticosteroids
50 A Double-blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis Completed NCT01166282 Phase 3

Search NIH Clinical Center for Juvenile Rheumatoid Arthritis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acetylsalicylic acid
Anakinra
Aurothioglucose
Betamethasone
Celecoxib
Choline magnesium trisalicylate
Ciclosporin
Corticotropin
Cortisone acetate
Cyclophosphamide
Dexamethasone
Diclofenac
Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Etanercept
Etodolac
Hydrocortisone
Ibuprofen
Ibuprofen
Leflunomide
Meclofenamic acid
Meloxicam
Methotrexate
Methotrexate
Methotrexate Sodium
Methylprednisolone
Naproxen
Naproxen
Naproxen sodium
oxaprozin
Oxaprozin
Prednisolone
Prednisone
Sodium aurothiomalate
solufenum
Sulfasalazine
tocilizumab
Tolmetin
Tolmetin
Tolmetin Sodium
Triamcinolone

Genetic Tests for Juvenile Rheumatoid Arthritis

Anatomical Context for Juvenile Rheumatoid Arthritis

MalaCards organs/tissues related to Juvenile Rheumatoid Arthritis:

41
Bone, Testes, T Cells, Eye, Skin, Liver, Monocytes

The Foundational Model of Anatomy Ontology organs/tissues related to Juvenile Rheumatoid Arthritis:

19
Joint

Publications for Juvenile Rheumatoid Arthritis

Articles related to Juvenile Rheumatoid Arthritis:

(show top 50) (show all 8021)
# Title Authors PMID Year
1
Therapeutic advances in juvenile idiopathic arthritis - associated uveitis. 38 17
30844943 2019
2
Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. 38 17
30999610 2019
3
Interleukin-6 in juvenile idiopathic arthritis. 38 17
30686091 2019
4
Tumor necrosis factor-alpha is a common genetic risk factor for asthma, juvenile rheumatoid arthritis, and systemic lupus erythematosus in a Mexican pediatric population. 9 38
19480843 2009
5
Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. 9 38
18766426 2009
6
[Immunotherapy using IL-6 receptor as the target]. 9 38
18974624 2008
7
Adalimumab in juvenile rheumatoid arthritis/juvenile idiopathic arthritis. 9 38
20476957 2008
8
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. 9 38
18716298 2008
9
Refractory vertebral sarcoidosis responding to infliximab. 9 38
18766126 2008
10
DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. 9 38
18332104 2008
11
The blockade of IL-6 signaling in rational drug design. 9 38
18473869 2008
12
Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in juvenile rheumatoid arthritis. 9 38
18078633 2007
13
Tuberculous uveitis after treatment with etanercept. 9 38
17364199 2007
14
Construction and purification of the murine p75-murine IgG1 fusion protein. 9 38
17502870 2007
15
Etanercept: a review of its use in the management of rheumatoid arthritis. 9 38
17521223 2007
16
Problems encountered during anti-tumour necrosis factor therapy. 9 38
16979537 2006
17
Etanercept and demyelinating disease in a patient with psoriasis. 9 38
16384777 2006
18
Etanercept for psoriasis in the pediatric population: experience in nine patients. 9 38
16445417 2006
19
Etanercept therapy in children with juvenile rheumatoid arthritis. 9 38
16341346 2005
20
Treatment with etanercept for patients with juvenile rheumatoid arthritis in Taiwan--a preliminary report. 9 38
16341347 2005
21
Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. 9 38
15801034 2005
22
Inhibitors of TACE and Caspase-1 as anti-inflammatory drugs. 9 38
16378499 2005
23
Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. 9 38
15468378 2004
24
HLA-DRB1 alleles and HLA-DRB1 shared epitopes are markers for juvenile rheumatoid arthritis subgroups in Colombian mestizos. 9 38
15120191 2004
25
[Polymorphism of human HLA-DRB1 leukocyte antigen alleles and its association to juvenile rheumatoid arthritis in a sample of Colombian mestizo children]. 9 38
14582328 2003
26
Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. 9 38
13130482 2003
27
Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis. 9 38
12739045 2003
28
DEK binding to class II MHC Y-box sequences is gene- and allele-specific. 9 38
12823858 2003
29
Anti-TNF therapy for other inflammatory conditions. 9 38
12463467 2002
30
Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. 9 38
12022325 2002
31
Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. 9 38
11083287 2000
32
Etanercept (Enbrel): update on therapeutic use. 9 38
11053088 2000
33
Stress induces increases in IL-6 production by leucocytes of patients with the chronic inflammatory disease juvenile rheumatoid arthritis: a putative role for alpha(1)-adrenergic receptors. 9 38
11024553 2000
34
Polymorphism at NRAMP1 and D2S1471 loci associated with juvenile rheumatoid arthritis. 9 38
10857800 2000
35
Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. 9 38
10717011 2000
36
Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNFalpha gene and HLA genes. 9 38
10616003 1999
37
Long-term follow-up of cytokines and soluble cytokine receptors in peripheral blood of patients with juvenile rheumatoid arthritis. 9 38
10505742 1999
38
Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity. 9 38
10025933 1999
39
Light activates reduction of methotrexate by NADPH in the ternary complex with Escherichia coli dihydrofolate reductase. 9 38
10063803 1999
40
Genetic regulation of macrophage activation: understanding the function of Nramp1 (=Ity/Lsh/Bcg). 9 38
10065630 1999
41
Autoantibodies to transcriptional regulation proteins DEK and ALY in a patient with systemic lupus erythematosus. 9 38
9952027 1999
42
Comparative sequence analysis of the human T cell receptor beta chain in juvenile rheumatoid arthritis and juvenile spondylarthropathies: evidence for antigenic selection of T cells in the synovium. 9 38
9506577 1998
43
Cytokines in juvenile rheumatoid arthritis. 9 38
9309198 1997
44
Immunity to cartilage link protein in patients with juvenile rheumatoid arthritis. 9 38
9150089 1997
45
HLA class II genes in Latvian patients with juvenile rheumatoid arthritis. 9 38
9027967 1997
46
Functional alpha 1-adrenergic receptors on leukocytes of patients with polyarticular juvenile rheumatoid arthritis. 9 38
8982123 1996
47
Autoreactivity to human heat-shock protein 60 predicts disease remission in oligoarticular juvenile rheumatoid arthritis. 9 38
8912504 1996
48
Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. 9 38
8843861 1996
49
Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. 9 38
7473488 1995
50
Interaction between HLA-DR and HLA-DP, and between HLA and interleukin 1 alpha in juvenile rheumatoid arthritis indicates heterogeneity of pathogenic mechanisms of the disease. 9 38
7558921 1995

Variations for Juvenile Rheumatoid Arthritis

ClinVar genetic disease variations for Juvenile Rheumatoid Arthritis:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 46;XY;t(8;9)(q13;p22)dn Translocation Pathogenic

Expression for Juvenile Rheumatoid Arthritis

Search GEO for disease gene expression data for Juvenile Rheumatoid Arthritis.

Pathways for Juvenile Rheumatoid Arthritis

Pathways related to Juvenile Rheumatoid Arthritis according to KEGG:

37
# Name Kegg Source Accession
1 Cytokine-cytokine receptor interaction hsa04060
2 JAK-STAT signaling pathway hsa04630

Pathways related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 TNFRSF1B TNF SLC11A1 S100A9 S100A12 LTA
2
Show member pathways
13.7 TNFRSF1B TNF LTA IL6 IL2RA IL1RN
3
Show member pathways
13.56 TNFRSF1B TNF LTA IL6 IL2RA IL1R1
4
Show member pathways
13.44 TNFRSF1B TNF LTA IL6 IL2RA IL1R1
5
Show member pathways
13.33 TNFRSF1B TNF LTA IL6 IL2RA IL1R1
6
Show member pathways
13.29 TNFRSF1B TNF LTA IL6 IL2RA IL1RN
7
Show member pathways
12.8 TNFRSF1B TNF LTA IL6 IL2RA
8
Show member pathways
12.79 TNF S100A12 IL6 IL1B IL18
9
Show member pathways
12.76 TNFRSF1B TNF LTA IL6 IL2RA IL1B
10
Show member pathways
12.75 TNFRSF1B TNF LTA IL6 IL1R1 IL1B
11
Show member pathways
12.7 TNFRSF1B TNF LTA IL1R1 IL1B
12
Show member pathways
12.66 TNFRSF1B TNF IL2RA IL18 HLA-DRB1 HLA-DQA1
13
Show member pathways
12.64 TNFRSF1B TNF LTA IL1R1 IL1B
14 12.6 TNFRSF1B TNF IL2RA IL1RN IL1B
15
Show member pathways
12.45 TNF IL6 IL2RA IL1R1 IL1B IL18
16
Show member pathways
12.36 TNF IL6 IL1B CRP
17
Show member pathways
12.35 TNF S100A9 IL6 IL1B
18
Show member pathways
12.33 TNF IL6 IL1R1 IL1B
19
Show member pathways
12.31 TNF IL1B HLA-DRB1 HLA-DQA1 HLA-DPB1
20
Show member pathways
12.31 TNF LTA IL6 IL2RA IL1B IL18
21 12.31 TNF LTA IL6 IL2RA IL1R1 HLA-DRB1
22
Show member pathways
12.25 TNF IL6 IL1RN IL1R1 IL1B IL18
23 12.25 TNF IL6 IL1B IL18 HLA-DRB1 HLA-DQA1
24
Show member pathways
12.21 TNF IL6 IL1R1 IL1B
25 12.2 TNF IL6 IL1RN IL1B
26
Show member pathways
12.12 TNFRSF1B IL6 IL2RA IL1R1 IL1B IL18
27
Show member pathways
12.09 TNF LTA IL6 IL1R1 IL1B IL18
28 12.06 TNF IL6 IL1R1 IL1B
29 12.05 TNFRSF1B TNF IL6 IL1B IL18
30
Show member pathways
12.04 IL2RA IL1R1 IL1B IL18 HLA-DRB1
31 12.03 TNFRSF1B TNF LTA IL6 IL1B
32 11.97 TNF IL6 IL1R1 IL1B
33 11.97 TNF LTA IL1R1 IL1B
34 11.91 TNF IL6 IL1B
35 11.86 HLA-DRB1 HLA-DQA1 HLA-DPB1
36 11.82 IL6 IL1B IL18
37 11.81 TNF LTA IL2RA IL1R1 IL1B IL18
38 11.79 TNF IL6 IL1B
39 11.77 TNF IL6 IL1B
40 11.76 TNF IL6 IL1RN IL1B IL18
41
Show member pathways
11.69 TNF IL6 IL1B
42 11.69 TNF IL6 IL1B
43 11.67 TNF IL6 IL1B IL18
44 11.67 TNF IL6 IL1B IL18 HLA-DRB1 HLA-DQA1
45 11.65 TNFRSF1B TNF LTA IL1R1
46 11.6 TNF IL6 IL1B IL18
47
Show member pathways
11.58 TNFRSF1B TNF LTA
48 11.56 TNF IL1B IL18
49 11.56 TNF IL6 IL1B BGLAP
50
Show member pathways
11.5 TNF IL1R1 IL1B

GO Terms for Juvenile Rheumatoid Arthritis

Cellular components related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 TNF S100A9 LTA IL6 IL1RN IL1B
2 endosome membrane GO:0010008 9.78 SLC11A1 HLA-DRB1 HLA-DQA1 HLA-DPB1
3 lysosome GO:0005764 9.77 SLC11A1 IL1B HLA-DRB1 HLA-DQA1 HLA-DPB1
4 trans-Golgi network membrane GO:0032588 9.69 HLA-DRB1 HLA-DQA1 HLA-DPB1
5 endocytic vesicle membrane GO:0030666 9.63 HLA-DRB1 HLA-DQA1 HLA-DPB1
6 ER to Golgi transport vesicle membrane GO:0012507 9.61 HLA-DRB1 HLA-DQA1 HLA-DPB1
7 transport vesicle membrane GO:0030658 9.58 HLA-DRB1 HLA-DQA1 HLA-DPB1
8 extracellular region GO:0005576 9.44 TNFRSF1B TNF S100A9 S100A12 LTA IL6
9 clathrin-coated endocytic vesicle membrane GO:0030669 9.43 HLA-DRB1 HLA-DQA1 HLA-DPB1
10 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.33 HLA-DRB1 HLA-DQA1 HLA-DPB1
11 MHC class II protein complex GO:0042613 9.13 HLA-DRB1 HLA-DQA1 HLA-DPB1
12 plasma membrane GO:0005886 10.27 TNFRSF1B TNF SLC11A1 S100A9 S100A12 LTA

Biological processes related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.96 TNF S100A12 IL1RN IL1B
2 response to lipopolysaccharide GO:0032496 9.94 TNFRSF1B SLC11A1 LTA IL1B
3 cellular response to lipopolysaccharide GO:0071222 9.92 TNFRSF1B TNF IL6 IL1RN IL1B
4 cytokine-mediated signaling pathway GO:0019221 9.92 TNFRSF1B TNF IL6 IL2RA IL1RN IL1R1
5 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.89 HLA-DRB1 HLA-DQA1 HLA-DPB1
6 defense response to Gram-positive bacterium GO:0050830 9.89 TNF LTA IL6 CRP
7 positive regulation of JNK cascade GO:0046330 9.88 TNF IL1RN IL1B
8 neutrophil chemotaxis GO:0030593 9.88 S100A9 S100A12 IL1RN IL1B
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 TNF S100A9 S100A12 IL6 IL1B IL18
10 tumor necrosis factor-mediated signaling pathway GO:0033209 9.87 TNFRSF1B TNF LTA
11 regulation of inflammatory response GO:0050727 9.87 TNF S100A9 IL1R1
12 positive regulation of inflammatory response GO:0050729 9.87 TNF S100A9 S100A12 IL18
13 interferon-gamma-mediated signaling pathway GO:0060333 9.86 HLA-DRB1 HLA-DQA1 HLA-DPB1
14 cellular response to organic cyclic compound GO:0071407 9.86 TNF IL1B IL18
15 humoral immune response GO:0006959 9.85 TNF LTA IL6
16 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 TNF IL6 IL18
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.84 TNF IL1B IL18
18 positive regulation of T cell proliferation GO:0042102 9.84 IL6 IL2RA IL1B HLA-DPB1
19 interleukin-1-mediated signaling pathway GO:0070498 9.83 IL1RN IL1R1 IL1B
20 antigen processing and presentation GO:0019882 9.81 HLA-DRB1 HLA-DQA1 HLA-DPB1
21 positive regulation of interleukin-6 production GO:0032755 9.81 TNF IL6 IL1RN IL1B
22 positive regulation of phagocytosis GO:0050766 9.8 TNF SLC11A1 IL1B
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.79 TNF IL1B IL18
24 negative regulation of neurogenesis GO:0050768 9.77 TNF IL6 IL1B
25 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.73 TNFRSF1B TNF IL1B
26 response to glucocorticoid GO:0051384 9.73 TNF IL6 IL1RN BGLAP
27 regulation of osteoclast differentiation GO:0045670 9.72 TNF BGLAP
28 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.72 TNF IL1B
29 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.72 HLA-DRB1 HLA-DQA1 HLA-DPB1
30 negative regulation of growth of symbiont in host GO:0044130 9.71 TNF LTA
31 inflammatory response to antigenic stimulus GO:0002437 9.71 IL2RA HLA-DRB1
32 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.7 IL1B IL18
33 T-helper 1 type immune response GO:0042088 9.7 IL18 HLA-DRB1
34 positive regulation of interferon-gamma production GO:0032729 9.7 TNF SLC11A1 LTA IL1R1 IL1B IL18
35 inflammatory response GO:0006954 9.7 TNFRSF1B TNF SLC11A1 S100A9 S100A12 IL6
36 positive regulation of chemokine biosynthetic process GO:0045080 9.68 TNF IL1B
37 regulation of establishment of endothelial barrier GO:1903140 9.68 TNF IL1B
38 interleukin-6 production GO:0032635 9.68 IL1B IL18
39 negative regulation of lipid storage GO:0010888 9.67 TNF IL6 CRP
40 positive regulation of glial cell proliferation GO:0060252 9.67 TNF LTA IL6 IL1B
41 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.65 TNF LTA
42 positive regulation of fever generation GO:0031622 9.65 TNF IL1B
43 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.65 IL6 IL1RN
44 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.65 IL1R1 IL1B IL18
45 sequestering of triglyceride GO:0030730 9.63 TNF IL1B
46 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 TNF IL1B
47 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.61 TNF LTA
48 positive regulation of neuroinflammatory response GO:0150078 9.56 TNF IL6 IL1B IL18
49 immune response GO:0006955 9.44 TNFRSF1B TNF SLC11A1 LTA IL6 IL2RA
50 positive regulation of JUN kinase activity GO:0043507 9.33 TNF

Molecular functions related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-1 receptor binding GO:0005149 9.32 IL1RN IL1B
2 RAGE receptor binding GO:0050786 9.26 S100A9 S100A12
3 MHC class II receptor activity GO:0032395 9.16 HLA-DRB1 HLA-DQA1
4 peptide antigen binding GO:0042605 9.13 HLA-DRB1 HLA-DQA1 HLA-DPB1
5 cytokine activity GO:0005125 9.1 TNF LTA IL6 IL1RN IL1B IL18

Sources for Juvenile Rheumatoid Arthritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....